Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings ...

Rodman & Renshaw analyst Brandon Folkes initiated coverage of Talphera (TLPH) with a Buy rating and $4 price target Invest with Confidence: ...

Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. Talphera ( NASDAQ:TLPH ) Third Quarter 2024 Results Key ...